FDA Approval Alert: The Need-to-Know | Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer

In February 2023, the FDA approved sacituzumab govitecan-hziy for the treatment of patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer in patients who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
HER2 Expression Determines Benefit of Sacituzumab Govitecan in HR+ Breast Cancer
Video
Apr 19, 2023 8:00 PM
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Sacituzumab Govitecan Aids Unmet Need in Pretreated HR+, HER2– Breast Cancer
Video
Apr 16, 2023 4:00 PM
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Efficacy Makes Sacituzumab Govitecan ‘Attractive’ in Advanced Breast Cancer
Video
Apr 13, 2023 12:00 PM
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.
Oncology On-the-Go Podcast: Sacituzumab Govitecan for HR+/HER2– Advanced Breast Cancer
Podcast
Feb 20, 2023 3:00 PM
Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.
An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.
Sacituzumab Govitecan Approval Gives ‘Meaningful’ Survival in Advanced HR+ Breast Cancer
Video
Feb 3, 2023 3:52 PM
An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.
Patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.
FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer
Article
Feb 3, 2023 3:39 PM
Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.